HISTOlogic transfoRmatIon of EGFR-mutant lung Cancer in the real-world setting. HISTORIC study

HISTOlogic transfoRmatIon of EGFR-mutant lung Cancer in the real-world setting. HISTORIC study - HISTORIC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040448

Enrollment

5000

Registered

2020-05-19

Start date

2020-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer with mutated EGFR

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.EGFR mutation-positive advanced stage lung cancer(TNM classification 8th edition) 2.Patients who started EGFR-TKI from January 1, 2012 to December 31, 2019

Exclusion criteria

Exclusion criteria: no criteria

Design outcomes

Primary

Measure	Time frame
incidence of histologic transformation	—

Countries

Japan

Contacts

Public ContactDaichi Fujimoto

Wakayama medical university Internal medicine III

daichi@wakayama-med.ac.jp073-441-0619

Outcome results